{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164010","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.805020+00:00","generated_at":"2026-06-14T04:10:11.837226+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Disc Medicine reports positive Phase 2 bitopertin data in EPP: PPIX down >40%, sunlight tolerance up >80-fold","bullets":["Mean reduction of whole-blood PPIX >40% in dose-dependent, sustained manner across 15 patients.","Two patients with longest follow-up: >80-fold (20 mg) and >200-fold (60 mg) increase in sunlight tolerance without prodrome.","Average weekly sunlight exposure rose from 344 min at baseline to 1,200 min at Week 24; time to prodrome increased >7-fold.","Patient-reported phototoxic reactions reduced 96% vs. baseline; all 10 patients at Day 43 reported disease much/a little better on PGIC.","Bitopertin well-tolerated: no serious AEs, no discontinuations, no grade >1 AEs, no meaningful hemoglobin changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164010","json":"https://secwatch.observer/filing/0001193125-23-164010.json","markdown":"https://secwatch.observer/filing/0001193125-23-164010.md","text":"https://secwatch.observer/filing/0001193125-23-164010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523164010/0001193125-23-164010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523164010/d350054d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:10:11.837226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}